Volunteer for Clinical Studies
Healthy volunteers help NIAID to evaluate treatment and prevention options for a wide range of diseases and conditions in our mission areas. Help us to improve human health.
NIAID Discovery Leads to Novel Probiotic for Eczema
NIAID researchers discovered that the bacteria, Roseomonas mucosa which occurs naturally as part of the typical microbiome present on healthy skin, can safely relieve eczema symptoms in adults and children. This discovery led to the availability of a topical eczema probiotic.
Type 1 Diabetes: Stages and the Journey to Treatment
Decades of NIH investment in basic research and clinical trials led to the approval of teplizumab, the first FDA-approved drug for delaying the onset of Type 1 diabetes in people at risk. This delay reduces the potential for severe long-term complications, thereby improving quality of life.
NIAID is the Lead Institute at the NIH Conducting Food Allergy Research
Food allergy research at NIAID encompasses basic research in allergy and immunology, epidemiological and observational studies to identify risk factors, and clinical trials of new strategies for prevention and treatment.
Acting Director Jeffery Taubenberger, M.D., Ph.D.
Jeffery K. Taubenberger, M.D., Ph.D.
Dr. Taubenberger was named the Acting Director of NIAID in April 2025. He oversees a $6.6 billion budget that supports research to advance the understanding, diagnosis, treatment and prevention of infectious, immunologic, and allergic diseases. He is known for sequencing, reconstruction, and characterization of the virus responsible for the 1918 influenza pandemic.
Learn more about Dr. Taubenberger
